{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:51:49Z","timestamp":1790203909281,"version":"4.1.0"},"reference-count":32,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018688","name":"Symphogen","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100018688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,26]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>NKG2A is a C-type lectin that heterodimerizes with CD94 creating an inhibitory immunoreceptor. S095029 is a fully human monoclonal IgG1 anti-NKG2A antibody with attenuated Fc-effector functions that specifically binds the NKG2A\/CD94 heterodimer, blocking the interaction with its ligand HLA-E. Sym021 is an anti-programmed cell death protein 1 (PD-1) IgG1 antibody. Preclinical data demonstrated that S095029 combined with Sym021 increases antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This first-in-human, open-label, multicenter study (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05162755\">NCT05162755<\/jats:ext-link>\n                      ) evaluated safety, tolerability, preliminary efficacy, pharmacokinetics and pharmacodynamics (PD) of S095029 as monotherapy or in combination with Sym021 in patients with advanced solid tumors. Monotherapy regimen included two doses of S095029 every 2 weeks (Q2W) followed by single-agent Sym021 (Q2W). Adverse events were defined per Common Terminology Criteria for Adverse Events V.5.0. Antitumor activity was evaluated per Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1. Cytokine secretion as PD markers and target engagement\/receptor occupancy were assessed in peripheral blood. Selected immune markers were assessed by multiplex immunofluorescence on tumor biopsies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of July 25, 2025, 21 patients with heavily pretreated solid tumors were treated with S095029 as a single agent (10, 30, 100, 300, 750 and 1,500\u2009mg) and 20 patients were treated with S095029 (30, 100, 300, 750 and 1,500\u2009mg) in combination with Sym021 (200\u2009mg). S095029 was well tolerated without dose-limiting toxicities for both monotherapy and combination with anti-PD-1. A maximum tolerated dose was not reached. Two patients (9.5%; uterine sarcoma, porocarcinoma) who received one cycle of S095029 monotherapy followed by Sym021 and two patients (10%; leiomyosarcoma, squamous cell carcinoma of unknown primary) who received S095029 in combination with Sym021 showed confirmed partial responses. None of these patients had received prior anti-PD-1 treatment. The clinical benefit rate (complete response+partial response+stable disease \u22656 months) by RECIST V.1.1 in all enrolled patients was 19.5%. S095029 serum concentrations increased with dose for both monotherapy and combination with Sym021. Full receptor occupancy was achieved starting at 30\u2009mg Q2W. Increases in levels of monokine induced by gamma interferon, macrophage inflammatory protein 1-beta and tumor necrosis factor-\u03b1 in peripheral blood were detected following treatment with S095029+Sym021 suggesting immune cell activation on treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The anti-NKG2A antibody S095029 in combination with anti-PD-1 Sym021 demonstrated a favorable safety profile and exhibited signal of antitumor activity in unselected, heavily pretreated patients with advanced malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05162755\">NCT05162755<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014325","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:15:16Z","timestamp":1778249716000},"page":"e014325","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05162755","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05162755","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05162755","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-3042","authenticated-orcid":false,"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Barve","sequence":"additional","affiliation":[{"name":"Mary Crowley Cancer Research Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[{"name":"The START Center for Cancer Research, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenophon","family":"Ianopoulos","sequence":"additional","affiliation":[{"name":"Servier BioInnovation, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Drean","sequence":"additional","affiliation":[{"name":"Institut de Recherches Internationales Servier, Gif-sur-Yvette, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Jorgen","family":"Skartved","sequence":"additional","affiliation":[{"name":"Servier, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-6656","authenticated-orcid":false,"given":"Agnes","family":"Hemon","sequence":"additional","affiliation":[{"name":"Institut Servier de Medecine Translationnelle, Gif-sur-Yvette, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chahrazade","family":"Kantari-Mimoun","sequence":"additional","affiliation":[{"name":"Institut Servier de Medecine Translationnelle, Gif-sur-Yvette, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"He","sequence":"additional","affiliation":[{"name":"Servier BioInnovation, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Askoxylakis","sequence":"additional","affiliation":[{"name":"Servier BioInnovation, Boston, Massachusetts, USA"},{"name":"Institut de Recherches Internationales Servier, Gif-sur-Yvette, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6327-0176","authenticated-orcid":false,"given":"Nehal","family":"Lakhani","sequence":"additional","affiliation":[{"name":"START Midwest, Grand Rapids, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026050807150975000_14.5.e014325.1","doi-asserted-by":"publisher","DOI":"10.1385\/IR:35:3:263"},{"key":"2026050807150975000_14.5.e014325.2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00152","article-title":"Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches","volume":"7","author":"Carotta","year":"2016","journal-title":"Front Immunol"},{"key":"2026050807150975000_14.5.e014325.3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4179"},{"key":"2026050807150975000_14.5.e014325.4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264562","article-title":"High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer","volume":"6","author":"Sun","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026050807150975000_14.5.e014325.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100354108"},{"key":"2026050807150975000_14.5.e014325.6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41571-019-0182-8","article-title":"The NKG2A immune checkpoint - a new direction in cancer immunotherapy","volume":"16","author":"Creelan","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026050807150975000_14.5.e014325.7","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-LB220","article-title":"Abstract LB220: S095029: a novel clinical-stage Fc-silenced NKG2A-blocking antibody with best-in-class potential","volume":"83","author":"Melander","year":"2023","journal-title":"Cancer Res"},{"key":"2026050807150975000_14.5.e014325.8","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1596514"},{"key":"2026050807150975000_14.5.e014325.9","doi-asserted-by":"crossref","first-page":"v488","DOI":"10.1093\/annonc\/mdz253.023","article-title":"A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)","volume":"30","author":"Spreafico","year":"2019","journal-title":"Ann Oncol"},{"key":"2026050807150975000_14.5.e014325.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0592"},{"key":"2026050807150975000_14.5.e014325.11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/psp4.12592","article-title":"Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer","volume":"10","author":"Spinosa","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026050807150975000_14.5.e014325.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.5"},{"key":"2026050807150975000_14.5.e014325.13","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202001134","article-title":"Cancer cells educate natural killer cells to a metastasis-promoting cell state","volume":"219","author":"Chan","year":"2020","journal-title":"J Cell Biol"},{"key":"2026050807150975000_14.5.e014325.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00267","article-title":"Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma","volume":"9","author":"Chiu","year":"2018","journal-title":"Front Immunol"},{"key":"2026050807150975000_14.5.e014325.15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681615","article-title":"Circulating and Tumor-Infiltrating NK Cells From Clear Cell Renal Cell Carcinoma Patients Exhibit a Predominantly Inhibitory Phenotype Characterized by Overexpression of CD85j, CD45, CD48 and PD-1","volume":"12","author":"Ziblat","year":"2021","journal-title":"Front Immunol"},{"key":"2026050807150975000_14.5.e014325.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.633205","article-title":"Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy","volume":"12","author":"Zalfa","year":"2021","journal-title":"Front Immunol"},{"key":"2026050807150975000_14.5.e014325.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275904","article-title":"Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy","volume":"14","author":"Fantini","year":"2023","journal-title":"Front Immunol"},{"key":"2026050807150975000_14.5.e014325.18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature New Biol"},{"key":"2026050807150975000_14.5.e014325.19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41379-019-0322-9","article-title":"The inhibitory receptor CD94\/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE\/\u03b22m overexpression","volume":"33","author":"Eug\u00e8ne","year":"2020","journal-title":"Mod Pathol"},{"key":"2026050807150975000_14.5.e014325.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.014"},{"key":"2026050807150975000_14.5.e014325.21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0655"},{"key":"2026050807150975000_14.5.e014325.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0298"},{"key":"2026050807150975000_14.5.e014325.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2095"},{"key":"2026050807150975000_14.5.e014325.24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007340","article-title":"Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026050807150975000_14.5.e014325.25","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov"},{"key":"2026050807150975000_14.5.e014325.26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18440","article-title":"Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial","volume":"8","author":"Aggarwal","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026050807150975000_14.5.e014325.27","unstructured":"ClinicalTrials.gov . Phase 1b\/2 platform study of select immunotherapy combinations in participants with advanced non-small cell lung cancer (nsclc). 2025."},{"key":"2026050807150975000_14.5.e014325.28","unstructured":"ClinicalTrials.gov . A study to evaluate the safety and the activity of s095029 as part of combination therapy in advanced gastroesophageal junction\/gastric cancers. 2025."},{"key":"2026050807150975000_14.5.e014325.29","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1245\/s10434-022-11665-3","article-title":"Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer","volume":"29","author":"Morinaga","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026050807150975000_14.5.e014325.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050906","article-title":"Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1\/PD-L1 Monoclonal Antibodies","volume":"17","author":"Roussot","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050807150975000_14.5.e014325.31","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026050807150975000_14.5.e014325.32","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","volume":"31","author":"Cascone","year":"2025","journal-title":"Nat Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:15:21Z","timestamp":1778249721000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,8]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014325"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014325","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}